Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.

Animals Apoptosis / drug effects Cell Line Cells, Cultured Clone Cells / metabolism Female Heterografts Humans Intracellular Signaling Peptides and Proteins / genetics Introns / genetics Janus Kinase 2 / antagonists & inhibitors MAP Kinase Signaling System / drug effects Male Mice Mutation Neoplasm Transplantation Neoplasms / drug therapy Phosphoproteins / analysis Phosphorylation Protein Serine-Threonine Kinases / genetics Proteome / analysis Proteomics RNA Splicing / genetics Remission Induction Y-Box-Binding Protein 1 / antagonists & inhibitors

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
12 2020

Historique:

received: 11 12 2018

accepted: 15 09 2020

pubmed: 27 11 2020

medline: 7 2 2021

entrez: 26 11 2020

Statut: ppublish

Résumé

Janus kinases (JAKs) mediate responses to cytokines, hormones and growth factors in haematopoietic cells

Identifiants

DOI: 10.1038/s41586-020-2968-3 PMID: 33239784

pubmed: 33239784

doi: 10.1038/s41586-020-2968-3

pii: 10.1038/s41586-020-2968-3

doi:

Substances chimiques

Intracellular Signaling Peptides and Proteins 0

Phosphoproteins 0

Proteome 0

Y-Box-Binding Protein 1 0

YBX1 protein, human 0

MKNK1 protein, human EC 2.7.1.-

JAK2 protein, human EC 2.7.10.2

Janus Kinase 2 EC 2.7.10.2

Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

157-163

Références

Darnell, J. E., Jr, Kerr, I. M. & Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415–1421 (1994).

doi: 10.1126/science.8197455

Perner, F., Perner, C., Ernst, T. & Heidel, F. H. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 8, 854 (2019).

doi: 10.3390/cells8080854

Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).

pubmed: 25426838 pmcid: 4290021

Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).

doi: 10.1056/NEJMoa1408617

Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45 (D1), D777–D783 (2017).

doi: 10.1093/nar/gkw1121

Deininger, M. et al. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 126, 1551–1554 (2015).

doi: 10.1182/blood-2015-03-635235

Harrison, C. N. et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30, 1701–1707 (2016).

doi: 10.1038/leu.2016.148

Humphrey, S. J., Azimifar, S. B. & Mann, M. High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics. Nat. Biotechnol. 33, 990–995 (2015).

doi: 10.1038/nbt.3327

Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384–388 (2015).

doi: 10.1038/nature14985

Climente-González, H., Porta-Pardo, E., Godzik, A. & Eyras, E. The functional impact of alternative splicing in cancer. Cell Rep. 20, 2215–2226 (2017).

doi: 10.1016/j.celrep.2017.08.012

Dolfini, D. & Mantovani, R. YB-1 (YBX1) does not bind to Y/CCAAT boxes in vivo. Oncogene 32, 4189–4190 (2013).

doi: 10.1038/onc.2012.521

Stickeler, E. et al. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 20, 3821–3830 (2001).

doi: 10.1093/emboj/20.14.3821

Wei, W. J. et al. YB-1 binds to CAUC motifs and stimulates exon inclusion by enhancing the recruitment of U2AF to weak polypyrimidine tracts. Nucleic Acids Res. 40, 8622–8636 (2012).

doi: 10.1093/nar/gks579

Kaelin, W. G., Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689–698 (2005).

doi: 10.1038/nrc1691

McCubrey, J. A. et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 22, 2080–2090 (2008).

doi: 10.1038/leu.2008.207

Meyer, S. C. Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms. Hematol. Oncol. Clin. North Am. 31, 627–642 (2017).

doi: 10.1016/j.hoc.2017.04.003

Stivala, S. et al. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J. Clin. Invest. 129, 1596–1611 (2019).

doi: 10.1172/JCI98785

Humphrey, S. J., Karayel, O., James, D. E. & Mann, M. High-throughput and high-sensitivity phosphoproteomics with the EasyPhos platform. Nat. Protocols 13, 1897–1916 (2018).

doi: 10.1038/s41596-018-0014-9

Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat. Methods 11, 319–324 (2014).

doi: 10.1038/nmeth.2834

Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).

doi: 10.1038/nbt.1511

Tyanova, S. & Cox, J. Perseus: a bioinformatics platform for integrative analysis of proteomics data in cancer research. Methods Mol. Biol. 1711, 133–148 (2018).

doi: 10.1007/978-1-4939-7493-1_7

Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

doi: 10.1093/bioinformatics/bts635

Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).

doi: 10.1093/bioinformatics/btt656

Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).

doi: 10.1093/nar/gkv007

Romero, J. P. et al. EventPointer: an effective identification of alternative splicing events using junction arrays. BMC Genomics 17, 467 (2016).

doi: 10.1186/s12864-016-2816-x

Schnöder, T. M. et al. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. J. Cancer Res. Clin. Oncol. 143, 807–820 (2017).

pubmed: 28233092

Webb, C. H. & Hertel, K. J. Preparation of splicing competent nuclear extracts. Methods Mol. Biol. 1126, 117–121 (2014).

doi: 10.1007/978-1-62703-980-2_8

Uckelmann, H. J. et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science 367, 586–590 (2020).

doi: 10.1126/science.aax5863

Lu, Z. H., Books, J. T. & Ley, T. J. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol. Cell. Biol. 25, 4625–4637 (2005).

doi: 10.1128/MCB.25.11.4625-4637.2005

Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584–596 (2010).

doi: 10.1016/j.ccr.2010.05.015

Cosgun, K. N. et al. Kit regulates HSC engraftment across the human-mouse species barrier. Cell Stem Cell 15, 227–238 (2014).

doi: 10.1016/j.stem.2014.06.001

Schnöder, T. M. et al. Epo-induced erythroid maturation is dependent on Plcγ1 signaling. Cell Death Differ. 22, 974–985 (2015).

doi: 10.1038/cdd.2014.186

Till, J. E. & McCULLOCH, E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14, 213–222 (1961).

doi: 10.2307/3570892

Quintás-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109–3117 (2010).

doi: 10.1182/blood-2009-04-214957

Heidel, F. H. et al. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J. Exp. Med. 210, 15–22 (2013).

doi: 10.1084/jem.20120596

Heidel, F. H. et al. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412–424 (2012).

doi: 10.1016/j.stem.2012.02.017

Arreba-Tutusaus, P. et al. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia 30, 1220–1225 (2016).

doi: 10.1038/leu.2015.292